Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) EBITDA (2016 - 2025)

Historic EBITDA for Biomerica (BMRA) over the last 16 years, with Q4 2025 value amounting to -$1.3 million.

  • Biomerica's EBITDA fell 3846.96% to -$1.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$4.0 million, marking a year-over-year increase of 2843.4%. This contributed to the annual value of -$5.0 million for FY2025, which is 1664.99% up from last year.
  • Per Biomerica's latest filing, its EBITDA stood at -$1.3 million for Q4 2025, which was down 3846.96% from $4000.0 recorded in Q3 2025.
  • Biomerica's EBITDA's 5-year high stood at $4000.0 during Q3 2025, with a 5-year trough of -$2.1 million in Q1 2021.
  • Its 5-year average for EBITDA is -$1.4 million, with a median of -$1.5 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 146036.21% in 2023, then soared by 10030.26% in 2025.
  • Biomerica's EBITDA (Quarter) stood at -$1.1 million in 2021, then plummeted by 44.69% to -$1.6 million in 2022, then rose by 7.83% to -$1.5 million in 2023, then skyrocketed by 36.7% to -$954000.0 in 2024, then plummeted by 38.47% to -$1.3 million in 2025.
  • Its EBITDA was -$1.3 million in Q4 2025, compared to $4000.0 in Q3 2025 and -$1.5 million in Q2 2025.